Cancers (Basel):与无患癌人群对照相比,癌症患者糖尿病发病率较高

2022-04-18 从医路漫漫 MedSci原创

癌症和糖尿病可能有共同的风险因素,如年龄较大、吸烟、肥胖、不健康的饮食、缺乏体育锻炼和饮酒过量。

背景:如今,癌症被认为是全球的一个主要公共卫生问题。据估计,2020年全球约有1930万新发癌症病例被确诊。由于癌症筛查、诊断和治疗的进步以及人口老龄化,全球癌症患者(包括存活至少5年的长期癌症幸存者)的数量正在增加。

先前的研究表明,癌症患者共患糖尿病可能很常见。发现糖尿病在癌症患者中比在非癌症人群中更普遍,这可能是由于几个原因。例如,癌症和糖尿病可能有共同的风险因素,如年龄较大、吸烟、肥胖、不健康的饮食、缺乏体育锻炼和饮酒过量。糖尿病还可能增加某些类型癌症的风险,如乳腺癌和结肠直肠癌,并使肝癌、胰腺癌和子宫内膜癌的风险增加一倍。除了癌症疾病,癌症治疗如放疗、糖皮质激素、靶向治疗、造血细胞移植(HCT)和雄激素剥夺治疗(ADT)也可能导致糖尿病风险增加。

在癌症患者中,糖尿病与较差的健康相关生活质量(HRQOL)、较高的医疗保健利用率以及癌症进展和死亡率增加的风险相关,这突出了了解癌症患者是否更有可能发展为糖尿病的临床重要性。

目前,关于癌症幸存者与非癌症人群糖尿病发病率的不一致结果已被报道。几项研究证明了发展后续糖尿病和癌症之间的正相关,而其他研究没有。最近的一项系统性综述通过汇总13项基于人群的队列研究和事件发生时间结果,报告了癌症和糖尿病之间的总体正相关,但该综述不包括非基于人群的研究和没有事件发生时间数据的基于人群的研究。

目的:我们旨在通过对队列研究的结果进行系统回顾和荟萃分析,评估癌症患者中是否有较高的糖尿病发病率。

方法:利用PubMed(MEDLINE)、Embase、Web of Science和Cochrane Library数据库,对癌症患者糖尿病发病率的队列研究进行系统的电子文献检索。随机效应荟萃分析用于汇总估计值。

结果:共纳入34篇文献,涉及360971名癌症患者和1819451名无癌症对照者。与无癌症人群相比,癌症患者糖尿病的合并相对风险(RR)增加1.42 (95%可信区间(CI):1.30–1.54,I2 = 95,τ2 = 0.0551,p < 0.01)。最高的相对风险出现在癌症诊断后的第一年(RR = 2.0695%可信区间为1.63–2.60)。

表1 队列研究a采用纽卡斯尔-渥太华量表(NOS)对纳入研究进行质量评估(研究按发表年份和第一作者排序)

图1 与未患癌症的对照组相比,癌症患者患糖尿病的总体相对风险。95%的预测区间提供了癌症和糖尿病之间真实关联的预测范围

图2 灵敏度分析

图3 偏倚漏斗图

结论:新发糖尿病与癌症呈正相关,但这种相关性因癌症类型而异。提倡进行更多大样本、长时间随访的前瞻性研究,以进一步研究这种联系和潜在机制。

 

原文出处:

Yang K,  Liu Z,  Thong MSY, et al.Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis.Cancers (Basel) 2022 Apr 02;14(7) .

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1775638, encodeId=c3421e75638ba, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 09 16:28:00 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823819, encodeId=fd3318238195b, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 10 15:28:00 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878512, encodeId=46c818e851270, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 27 14:28:00 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289758, encodeId=b91f1289e5828, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601496, encodeId=5c91160149659, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=)]
    2022-05-09 amyloid
  2. [GetPortalCommentsPageByObjectIdResponse(id=1775638, encodeId=c3421e75638ba, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 09 16:28:00 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823819, encodeId=fd3318238195b, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 10 15:28:00 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878512, encodeId=46c818e851270, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 27 14:28:00 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289758, encodeId=b91f1289e5828, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601496, encodeId=5c91160149659, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1775638, encodeId=c3421e75638ba, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 09 16:28:00 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823819, encodeId=fd3318238195b, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 10 15:28:00 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878512, encodeId=46c818e851270, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 27 14:28:00 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289758, encodeId=b91f1289e5828, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601496, encodeId=5c91160149659, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=)]
    2022-12-27 anminleiryan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1775638, encodeId=c3421e75638ba, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 09 16:28:00 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823819, encodeId=fd3318238195b, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 10 15:28:00 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878512, encodeId=46c818e851270, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 27 14:28:00 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289758, encodeId=b91f1289e5828, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601496, encodeId=5c91160149659, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1775638, encodeId=c3421e75638ba, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Mon May 09 16:28:00 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823819, encodeId=fd3318238195b, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 10 15:28:00 CST 2022, time=2022-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878512, encodeId=46c818e851270, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Tue Dec 27 14:28:00 CST 2022, time=2022-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289758, encodeId=b91f1289e5828, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601496, encodeId=5c91160149659, content=<a href='/topic/show?id=5baa5299111' target=_blank style='color:#2F92EE;'>#患癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52991, encryptionId=5baa5299111, topicName=患癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=888f18872716, createdName=lq0307, createdTime=Tue Apr 19 07:28:00 CST 2022, time=2022-04-19, status=1, ipAttribution=)]
    2022-04-19 lq0307

相关资讯

Diabetologia |哈佛研究:坚持吃草,尤其是健康的植物性饮食能明显降低2型糖尿病的风险

以植物为基础的饮食,特别是富含健康植物食物的饮食,与2型糖尿病的风险较低有关

柳叶刀:近20万人数据显示,新冠感染一年内,这种疾病的风险增加40%!

柳叶刀子刊:这项针对近20万人的大规模研究显示,与未感染者相比,新冠病毒感染者1年内罹患糖尿病的风险显著提高了40%!

Diabetologia:1型糖尿病患者低HbA1c和低血压是保护性心血管健康指标

1型糖尿病患者低HbA1c和低血压是保护性心血管健康指标。

Lancet Diabetes Endocrinol:达格列净在2型糖尿病年轻患者中的疗效和安全性

对于 型糖尿病儿童、青少年和年轻成人患者,在标准治疗方案上加用达格列净对HbA1c水平的影响无明显差异

Cardiovasc Diabetol:长期服用二甲双胍对糖尿病患者心肌肌钙蛋白水平的影响

2 型糖尿病患者的循环心肌肌钙蛋白水平长期升高,是心血管终点的一个既定预测因子和亚临床心肌损伤的预后标志物

Eur Heart J:阿司匹林对糖尿病患者痴呆和认知功能的影响

阿司匹林对痴呆症的风险没有很大的比例效应。每日服用低剂量阿司匹林长达平均7.4年,对广义或狭义痴呆结局的风险均无统计学意义。